HC Wainwright Reaffirms Buy Rating for CalciMedica (NASDAQ:CALC)

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

CalciMedica Price Performance

Shares of CALC opened at $1.94 on Thursday. The business’s 50-day moving average is $1.81 and its 200-day moving average is $2.56. The company has a market capitalization of $27.11 million, a price-to-earnings ratio of -1.80 and a beta of 1.24. CalciMedica has a fifty-two week low of $1.43 and a fifty-two week high of $6.02.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. Equities research analysts expect that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of CalciMedica

Several large investors have recently modified their holdings of the company. First Manhattan CO. LLC. bought a new position in shares of CalciMedica in the first quarter worth about $25,000. 180 Wealth Advisors LLC acquired a new stake in CalciMedica in the 1st quarter valued at approximately $31,000. Cambridge Investment Research Advisors Inc. acquired a new stake in CalciMedica in the 1st quarter valued at approximately $45,000. Cetera Investment Advisers increased its position in CalciMedica by 37.1% in the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares during the period. Finally, Wealthedge Investment Advisors LLC acquired a new position in shares of CalciMedica during the fourth quarter worth approximately $98,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.